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Background: The bioactive lysophospholipids phosphatidic acid (PA), lysophosphatidic acid (LPA) and
sphingosine-1-phosphate (S1P) have been implicated in mediating cell migration, proliferation and apoptosis,
inflammation, angiogenesis and fibrosis. This study was conducted to measure the levels of PA, LPA, LPA-producing
enzymes phospholipase A1/A2 (PLA1A/PLA2, respectively) and acylgylycerol kinase (AGK), the S1P receptor S1PR1, the
S1P catabolising enzyme S1P lyase (SPL) and 5-lipoxygenase in the vitreous fluid from patients with proliferative
diabetic retinopathy (PDR). In addition, we investigated the correlations between the levels of PA and LPA and
the levels of the inflammatory and endothelial dysfunction biomarker soluble vascular cell adhesion molecule-1 (sVCAM-1).
Methods: Vitreous samples from 34 PDR and 29 nondiabetic patients were studied by biochemical and enzyme-linked
immunosorbent assays and Western blot analysis.
Results: PA, LPA and sVCAM-1 levels in vitreous samples from PDR patients were significantly higher than those
in nondiabetic patients. Significant correlations were observed between levels of LPA and levels of PA and
sVCAM-1. Western blot analysis revealed a significant increase in the expression of PLA1A, AGK, S1PR1 and SPL
in vitreous samples from PDR patients compared to nondiabetic controls, whereas PLA2 and 5-lipoxygenase
were not detected.
Conclusions: Our findings suggest that the enzymatic activities of PLA1A and AGK might be responsible for
increased synthesis of LPA in PDR and that PLA1A, but not PLA2 is responsible for deacylation of PA to generate
LPA. S1PR1 and SPL might regulate inflammatory, angiogenic and fibrogenic responses in PDR.
Keywords: Proliferative diabetic retinopathy, Lysophospholipids, Phosphatidic acid, Lysophosphatidic acid,
Sphingosine-1-phosphate lyase, Phospholipase A1Background
Proliferative diabetic retinopathy (PDR) is characterized
by inflammation, gradual progressive retinal vasculopa-
thy leading to endothelial cell dysfunction, breakdown of
the blood-retinal barrier, ischemia-induced angiogenesis
and expansion of extracellular matrix resulting in the
outgrowth of fibrovascular membranes at the vitreret-
inal interface. Formation of fibrovascular tissue often* Correspondence: abuasrar@ksu.edu.sa
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otherwise stated.leads to severe visual loss due to vitreous hemorrhage
and/or traction retinal detachment. Development of PDR
is a complex process where matrix metalloproteinases
(MMPs), cytokines, chemokines and growth factors inter-
act with each other to promote inflammation, alterations
of the retinal microvasculature, angiogenesis and fibrosis
[1-5]. In recent years, bioactive lysophospholipids, such as
phosphatidic acid (PA), lysophosphatidic acid (LPA) and
sphingosine-1-phosphate (S1P) have been implicated
in mediating a variety of biological activities including
cell proliferation, migration and apoptosis, inflammation,
tumor cell progression and metastasis, angiogenesis, fibrosisntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain Dedica-
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Abu El-Asrar et al. Lipids in Health and Disease 2014, 13:187 Page 2 of 8
http://www.lipidworld.com/content/13/1/187and secretion of MMPs, cytokines and chemokines [6-10].
These findings strongly support a role for these mole-
cules in PDR development and progression.
Bioactive lyphophospholipids are synthesized and de-
graded by a complex set of metabolic pathways. Several
routes are proposed for LPA production. LPA can be
produced by secretory phospholipase A1 or A2 (PLA1/
PLA2, respectively) - catalyzed deacylation of PA [11-13].
PLA2 enzyme also regulates the provision of arachidonic
acid to both the cyclooxygenase and lipoxygenase-derived
eicosanoids [14]. The other mechanism involves the hy-
drolysis of the lysophospholipid lysophosphatidylcholine
by the lysophospholipase D activity of the ectoenzyme
autotaxin. Another proposed pathway for LPA generation
is through phosphorylation of monoacylglycerols by a spe-
cific lipid kinase, acylglycerol kinase (AGK) [11-13]. In a
previous study, we demonstrated elevated levels of LPA
and AGK in the vitreous fluid from patients with PDR,
whereas autotaxin was downregulated [15]. However, the
molecular mechanisms and enzyme pathways involved in
LPA production in the diabetic ocular microenvironment
are not yet fully understood.
S1P has been well characterized as an agonist of five
G-protein coupled receptors, named S1PR1-5. Extensive
evidence has accumulated implicating S1P-S1PR1 inter-
action in regulating cell motility and survival, angiogenesis,
vascular maturation and tone, neurogenesis and lympho-
cyte trafficking [16-18]. In addition, S1PR1 was demon-
strated to be a critical component of vascular endothelial
growth factor (VEGF)-induced angiogenic response [19].
S1P lyase (SPL) is a stress-induced intracellular enzyme
responsible for irreversible degradation of S1P to hexa-
decenal and phosphoethanolamine. Thus, this enzyme
is considered to be a major control point to regulate
S1P concentrations in cells [20]. Indeed, constitutive
knock-out of SPL in mice leads to a pronounced in-
crease of S1P levels in tissues and serum [21,22].Figure 1 Comparisons of mean phosphatidic acid (PA), lysophosphati
(sVCAM-1) in vitreous fluid samples from patients with proliferative
The difference between the two means was statistically significant at 5% leThe aim of this study was to measure the levels of PA,
LPA and the LPA-producing enzymes PLA1, PLA2 and
AGK in the vitreous fluid from patients with PDR and
to correlate the levels of PA and LPA with the levels of
the inflammation and endothelial dysfunction biomarker
soluble vascular cell adhesion molecule-1 (sVCAM-1).
In addition, we investigated the expression of S1PR1,
SPL and 5-lipoxygenase in the vitreous fluid from pa-
tients with PDR.
Results
Levels of PA, LPA, and sVCAM-1 in vitreous samples
With the use of fluorometric assay kit, we detected PA
in all analysed vitreous fluid samples from patients with
PDR (n = 26) and control patients without diabetes (n = 16).
PA mean level in vitreous samples from PDR patients
(22.8 ± 3.8 μM) was significantly higher than that in
control patients without diabetes (10.4 ± 1.2 μM) (p < 0.0001;
Mann–Whitney test) (Figure 1).
With the use of ELISA assay kits, we detected LPA
and sVCAM-1 in all analysed vitreous fluid samples
from patients with PDR and control patients without
diabetes. The mean level of LPA in vitreous samples
from PDR patients (n = 26) (0.6 ± 0.7 μM) was signifi-
cantly higher than that in control patients without dia-
betes (n = 18) (0.1 ± 0.2 μM) (p < 0.0001; Mann-Whiney
test). Similarly, the mean level of sVCAM-1 in vitreous
samples from PDR patients (n = 24) (12.8 ± 10.1 ng/ml)
was significantly higher than that in control patients
without diabetes (n = 25) (7.7 ± 3.1 ng/ml) (p = 0.015;
Mann–Whitney test) (Figure 1).
Correlations
There was a significant positive correlation between vitre-
ous fluid levels of PA and LPA (r = 0.52; p = 0.001). In
addition, there was a significant positive correlation be-
tween vitreous fluid levels of LPA and sVCAM-1 (r = 0.36;dic acid (LPA) and soluble vascular cell adhesion molecule-1
diabetic retinopathy (PDR) and nondiabetic control patients.
vel of significance.
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nificant correlation between PA and sVCAM-1.
Expression levels of PLA1A, PLA2, AGK, S1PR1, SPL, and
5-lipoxygenase in vitreous samples
Western blot analysis was used to quantify the ex-
pression levels of PLA1A, PLA2, AGK, S1PR1, SPL
and 5-lipoxygenase in vitreous fluid samples from pa-
tients with PDR (n = 16) and control patients without
diabetes (n = 16). We demonstrated that PLA1A, AGK,
S1PR1 and SPL were detected in all vitreous fluid samples
from patients with PDR and control patients without dia-
betes (Figure 3).
On the other hand, PLA2 and 5-lipoxygenase were not
detected in vitreous fluid samples from patients with
PDR and nondiabetic control patients. Western blot ana-
lysis was also used to quantify the expression levels of
PLA2 and 5-lipoxygenase in serum samples from patients
with PDR (n = 12) as a positive control. Western blot ana-
lysis revealed expression of PLA2 and 5-lipoxygenase in
all serum samples (Figure 4).
Densitometric analysis of the bands demonstrated a sig-
nificant increase in PLA1A (p = 0.042; Mann–Whitney test),
AGK (p < 0.001; Mann–Whitney test), S1PR1 (p < 0.001;
Mann–Whitney test), and SPL (p = 0.032; Mann–Whitney
test) expressions in vitreous fluid samples from PDR patients
compared to control patients without diabetes (Figure 3).
The protein expression of PLA1A in the vitreous sam-
ples from PDR patients was increased by about 3.53-fold
compared to control patients without diabetes. AGK ex-
pression in the vitreous samples from patients with PDR
was upregulated by about 2.73-fold as compared to the
vitreous samples from control patients without diabetes.
The expression of S1PR1 in the vitreous samples from
PDR patients was upregulated by about 2.65-fold as
compared to the vitreous samples from control patientsFigure 2 Significant positive correlations between vitreous fluid level
vitreous samples from 25 proliferative diabetic retinopathy and 15 no
molecule-1 (sVCAM-1) in vitreous samples from 22 proliferative diabewithout diabetes. SPL protein expression in the vitreous
samples from PDR patients was increased by about
2.1-fold as compared to control patients without diabetes.
Discussion
This study shows for the first time increased local levels
of PA, PLA1A, S1PR1 and SPL in the vitreous fluid from
patients with PDR as compared to nondiabetic control
patients, whereas PLA2 and 5-lipoxygenase were un-
detectable in both diabetic patients and controls. The
proinflammatory LPA is a simple potent bioactive phospho-
lipid with many important biological functions, such as me-
diating cell proliferation, migration and survival, suppression
of apoptosis, angiogenesis, fibrosis and MMP-9, cytokine
and chemokine secretion [6-8,23] LPA is a potent activator
of several transcription factors and signaling pathways
which are known to be involved in the pathophysiology
of diabetic retinopathy [24-28]. LPA target genes in-
clude those involved in inflammation, angiogenesis and
fibrosis [25-27,29-31] which are the pathological hall-
marks of PDR [1-5]. The current data show a signifi-
cant correlation between the vitreous levels of LPA
and that of the inflammatory and endothelial dysfunc-
tion biomarker sVCAM-1. Previous studies reported
that LPA activates human endothelial cells to upregu-
late the expression of VCAM-1 [29].
In the present study we report that PA, LPA, PLA1A
and AGK were significantly upregulated in the vitreous
fluid from patients with PDR, whereas PLA2 was not de-
tected. These results suggest that PLA1A, but not PLA2
might be responsible for deacylation of PA to generate
LPA and that PLA1A plays a pivotal role in the develop-
ment and progression of PDR. In a previous study, we
demonstrated that autotaxin was significantly downregu-
lated in the vitreous fluid from patients with PDR and in
the retinas of diabetic rats [15]. The results of the presents of lysophosphatidic acid (LPA) and phosphatidic acid (PA) in
ndiabetic control patients (A) and soluble vascular cell adhesion
tic retinopathy and 12 nondiabetic control patients (B).
Figure 3 Comparisons of mean band intensities for phospholipase A1A (PLA1A), acylglycerol kinase (AGK), sphingosine-1-phosphate
receptor 1 (S1PR1) and sphingosine-1-phosphate lyase (SPL) in vitreous samples from proliferative diabetic retinopathy (PDR) patients
(n = 16) and nondiabetic control patients (n = 16). A representative set of samples is shown. The difference between the two means was
statistically significant at 5% level of significance.
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zymatic activities of PLA1A and AGK might be respon-
sible for the increased synthesis and secretion of LPA in
PDR. In the present study, 5-lipoxygenase was not de-
tected in the vitreous fluid from patients with PDRFigure 4 Western blot analysis of phospholipase A2 (PLA2) and
5-lipoxygenase in serum samples from patients with proliferative
diabetic retinopathy. A representative set of samples is shown.
There is expression of PLA2 and 5-lipoxygenase in serum samples.suggesting that the PLA2 enzymatic activity is not in-
volved in the progression of PDR.
S1P is a bioactive sphingolipid metabolite and the final
common product of complex sphingolipid metabolism.
S1P acts through its cognate G protein-coupled receptors to
promote cell survival and inhibit apoptosis. S1P-mediated
events are also implicated in pathological angiogenesis, in-
flammation, fibrosis, the response to ischemic injury and
cancer progression. In addition, S1P regulates lymphocyte
trafficking, promotes DNA synthesis, cell proliferation and
cell migration and plays a major role in endothelial integrity.
These findings strongly support a role for S1P signaling in
promoting tumorigenesis and cancer progression [20]. SPL
catalyzes the irreversible degradation of S1P. SPL is, thus, in
a strategic position to regulate these same processes by re-
moving the available S1P signaling pools [20]. By reducing
S1P pools available for autocrine and paracrine signaling,
overexpression of SPL promotes apoptosis under stress con-
ditions including DNA damage [20,32]. In addition, Huwiler
et al. [33] demonstrated that SPL disrupts the biological
Abu El-Asrar et al. Lipids in Health and Disease 2014, 13:187 Page 5 of 8
http://www.lipidworld.com/content/13/1/187effects stimulated by extracellular S1P, including aberrant
angiogenesis, tumorigenesis, malignant progression and
fibrosis.
In the present study, SPL was upregulated in the vitre-
ous from patients with PDR. Recently, several studies re-
ported upregulation of SPL expression in animal models
of cardiac ischemia [21] and acute lung injury [22] and
in human breast cancer [34]. Bandhuvula et al. [21]
demonstrated that cardiac ischemia induced activation
of SPL and that inhibition of SPL by either genetic or
pharmacologic approaches reduced SPL activity, raised
S1P levels, reduced infarct size and increased functional
recovery. These findings reveal that SPL is an ischemia-
induced enzyme. In a mouse model of acute lung injury,
SPL levels are enhanced and S1P levels are decreased.
Inhibition of SPL resulted in increased S1P levels, and
protected against cytokine release, inflammation and
endothelial barrier dysfunction. In addition, it was demon-
strated that S1P is a major barrier-protective agent re-
sponsible for maintenance of vascular integrity in vitro
and in vivo [22]. These findings suggest that upregulation
of SPL in the vitreous fluid from patients with PDR may
contribute to diabetes-induced retinal neurodegeneration
[35,36] and vasculopathy. On the other hand, SPL disrupts
S1P-induced tumorigenesis and malignant progression, fi-
brosis and aberrant angiogenesis [33] and loss of SPL ex-
pression is significantly associated with aggressive cancers
[32,37]. These findings suggest that the upregulation of
SPL in the vitreous fluid from patients with PDR may be a
protective antiangiogenic and antifibrogenic eye response
to counterbalance the activity of angiogenic and fibrogenic
factors in PDR.
Extensive evidence has accumulated implicating S1PR1
in regulating migration of endothelial cells, angiogenesis,
survival and lymphocyte trafficking [16-19]. In the present
study, we demonstrated that S1PR1 levels were signifi-
cantly upregulated in the vitreous from patients with PDR.
Increased levels of S1PR1 may reflect enhanced tissue
S1PR1 expression in the diabetic ocular microenviron-
ment and increased shedding by proteinases as a result of
chronic ongoing inflammation. Furthermore, increased
levels of S1PR1 in the vitreous fluid from patients with
PDR might bind the ligand S1P preventing S1P from
reaching the cell surface S1PR1. Our results suggest that
elevated levels of S1PR1 potentially negatively regulate
S1P signaling and disrupt the biological effects mediated
by extracellular S1P.
The vitreous fluid, collected from patients with PDR
during pars plana vitrectomy, is an ideal material for
analysis of local, intraocular concentrations of selected
proteins which take part of this pathology. However,
when measuring these factors in the vitreous, some con-
siderations should be kept in mind. Vitreous hemorrhage
and breakdown of the blood-retinal barrier can provide aninflux of serum proteins into vitreous fluid. However, in a
previous study, we demonstrated that there was no correl-
ation between hemoglobin levels, as a measure of the
amount of erupted blood, and total protein levels in vitre-
ous fluid from patients with PDR [2]. Although VEGF is
abundant in serum, the levels of VEGF in the vitreous
fluid did not differ significantly between eyes with non-
diabetic massive vitreous hemorrhage and nondiabetic
eyes without vitreous hemorrhage. On the other hand,
the concentration of VEGF was significantly higher in
eyes with PDR than in nondiabetic eyes with massive
vitreous hemorrhage or nondiabetic eyes with no vitreous
hemorrhage [38]. Furthermore, in a previous study, we re-
ported that brain-derived neurotophic factor (BDNF) was
not detected in vitreous samples from patients with PDR
and nondiabetic control patients, whereas BDNF was de-
tected in all serum samples from patients with PDR and
nondiabetic controls [39]. Similarly, in the present study,
we demonstrated that PLA2 and 5-lipoxygenase were not
detected in vitreous samples from PDR patients, whereas
PLA2 and 5-lipoxygenase were detected in serum samples
from patients with PDR. Flow cytometric analysis showed
the presence of inflammatory cells in the vitreous fluid
from patients with PDR [40,41]. In addition, endothelial
cells, leukocytes and myofibroblasts have been found in fi-
brovascular epiretinal membranes from patients with PDR
[1,42,43]. In a previous study, we demonstrated the ex-
pression of AGK and the LPA receptor LPA1 by vascular
endothelial cells and stromal cells in PDR fibrovascular
epiretinal membranes [44]. Taken together, these find-
ings suggest that local cellular production is the rele-
vant source of the studied factors within the ocular
microenvironment.
Conclusions
Our previous study [15], together with the present re-
sults, suggest that the enzymatic activities of PLA1A and
AGK might be responsible for the increased synthesis of
LPA in PDR and that PLA1A, but not PLA2 is respon-
sible for deacylation of PA to generate LPA. Increased
expression of S1PR1 and SPL in the vitreous fluid from
patients with PDR might regulate the inflammatory, an-
giogenic and fibrogenic responses in PDR. Our findings
suggest that bioactive lysophospholipids could be a novel
target in diabetic retinopathy.
Methods
Vitreous samples
Undiluted vitreous fluid samples (0.3 – 0.6 ml) were ob-
tained from 34 patients with PDR during pars plana vitrec-
tomy. The indications for vitrectomy were traction retinal
detachment, and/or nonclearing vitreous hemorrhage. The
diabetic patients were 23 males and 11 females, whose ages
ranged from 26 to 86 years with a mean of 50.15 ± 16.7 years.
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with a mean of 18.1 ± 5.9 years. Twenty patients had
insulin-dependent diabetes mellitus, and 14 patients
had noninsulin-dependent diabetes mellitus. At pres-
entation, the fasting blood glucose was uncontrolled in
22 patients and controlled in 12 patients. Seventeen
patients were receiving treatment for hypertension, 9
patients had diabetic nephropathy, and 11 patients had
cardiovascular disease. The control group consisted of
29 patients who had undergone vitrectomy for the
treatment of rhegmatogenous retinal detachment (RD)
with no proliferative vitreoretinopathy. Controls were
free from systemic disease and were 20 males and 9 fe-
males whose ages ranged from 27 to 66 years with a
mean of 49.3 ± 15.5 years. Vitreous samples were col-
lected undiluted by manual suction into a syringe through
the aspiratin line of vitrectomy, before opening the infu-
sion line. The samples were centrifuged (5000 rpm for
10 min, 4°C) and the supernatants were aliquoted and fro-
zen at −80°C until assay. The study was conducted ac-
cording to the tenets of the Declaration of Helsinki. All
the patients were candidates for vitrectomy as a surgical
procedures. All patients signed a preoperative informed
written consent and approved the use of the excised vitre-
ous fluid. The study design and the protocol were ap-
proved by the Research Centre and Institutional Review
Board of the College of Medicine, King Saud University.
Enzyme-linked immunosorbent assay kits
Enzyme-linked immunosorbent assay (ELISA) kit for hu-
man sVCAM-1 (Quantikine Human soluble Vascular Cell
Adhesion Molecules-1, Cat No: DVC00) was purchased
from R&D Systems, Minneapolis, MN. LPA (Lysopho-
sphatidic acid, Cat No: K-2800) ELISA was purchased
from Echelon Biosciences Inc, Utah, USA. The detection
limit for sVCAM-1 was 0.6 ng/mL. The plate readings
were done using FLUOstar Omega-Miroplate reader from
BMG Labtech, Offenburg, Germany.
Measurement of human sVCAM-1 and LPA
The quantifications of the level of sVCAM-1 and LPA in
the vitreous fluid were determined according to the man-
ufacturer’s instruction. For sVCAM-1 detection, 100 μL of
undiluated vitreous samples were added into each ELISA
well coated with primary antibody. Following sample incu-
bation, secondary antibody against sVCAM-1, conjugated
to horseradish peroxidase was added to each well of the
ELISA plate. For LPA, a mix of 100 μL of undiluted vitre-
ous and anti-LPA antibody (sample to antibody at ratio of
4:1) were added in the respective wells. After incubation
and washing each well, substrate mix solution of hydrogen
peroxide and tetramethyl benzidine (1:1) was added for
colour development. The reaction was completed by the
addition of 2 N sulfuric acid and optical density (OD) wasread at 450 nm in microplate reader. Each assay was per-
formed in duplicate. With the use of a 4-parameter fit lo-
gistic curve equation, the actual concentration for each
sample was calculated.
Measurement of human total PA
The quantification of the level of total PA in the vitreous
fluid was done according to the manufacturer’s instruc-
tion (Cat No: DVC00, Cayman Chemical Company, Ann
Arbor, MI). The PA assay kit uses the fluorescence based
methods wherein the presence of peroxidase, H2O2 re-
acts with ADHP (10-acetyl-3,7-dihydroxyphenoxazine)
to give highly fluorescent compound known as resorufin.
The total lipids were first extracted from the each vitre-
ous samples and were dried under a gentle stream of ni-
trogen. The sample was resuspended in 1% triton X-100
and was ready to use for the analysis or storage. After
adding 10 μL of each samples in 96 well plate, the reac-
tion was initiated by adding 40 μL of lipase and the plate
was incubated at 37°C for 1 hour. The detector mixture
was prepared as detailed and 50 μL of which was added
to all well and was kept for another 30 minutes at room
temperature. The fluorescence was read using an excita-
tion wavelength of 530 nm and emission wavelength of
585 using Gemini XPS fluorescence microplate reader
(Molecular Devices, LLC, Sunnyvale, CA). Each assay
was performed in duplicate. Using the linear regression
curve equation for standard, the concentration for each
sample was calculated.
Western blot analysis for PLA1A, PLA2, AGK, S1PR1, SPL
and 5 -lipoxygenase in human vitreous
To determine the expression levels of PLA1A, PLA2,
AGK, S1PR1, SPL and 5 -lipoxygenase in the vitreous
samples, equal volume of samples were boiled in Laemm-
li’s sample buffer (1:1, v/v, reducing condition) for 10 min.
Equal volume of lysed solution (15 μL) was loaded and
separated on 8–10% SDS-polyacrylamide gels (SDS-
PAGE) and transferred onto nitrocellulose membranes.
After protein transferring, the membrane was blocked
(1.5 h, room temperature) with 5% non-fat milk made
in Tris-buffered saline containing 0.1%Tween-20 (TBS-T).
For immunodetection of S1PR1, SPL, PLA1A, PLA2,
AGK and 5-lipoxygenase, the membrane was incubated
overnight at 4°C with rabbit polyclonal anti-S1PR1
(1:300; Cat No:10005228, Cayman Chemical Company),
goat polyclonal anti-SPL (1 μg/ml; Cat No: AF5535, R&D
Systems), rabbit polyclonal anti-PLA1 (1:1000; Cat No:
ab139728, Abcam, UK), rabbit polyclonal anti-PLA2
(1:1000; Cat No: ab23705, Abcam), rabbit polyclonal
anti-AGK (1:500; Cat No: ab77266, Abcam) and rabbit
polyclonal anti-5-lipoxygenase (1:1000; Cat No: ab39347,
Abcam). After overnight incubation with primary antibody,
the membrane was washed three times with TBS-T (5 min
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the membrane was incubated at room temperature for
1.5 h with anti-rabbit secondary horseradish peroxidase-
conjugated antibody (1:2,000, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) and for SPL with anti-goat secondary
horseradish peroxidase-conjugated antibody (1:5,000, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA). After incuba-
tions with secondary antibodies, membranes were washed
four times with TBS-T (5 min each) and the immunoreac-
tivity of bands was visualized on a high-performance
chemiluminescence machine (G: Box Chemi-XX8 from
Syngene, Synoptic Ltd.Cambridge, UK) by using enhanced
chemiluminescence plus Luminol (SC-2048, Santa Cruz
Biotechnology) and quantified by densitometric ana-
lysis using image processing and analysis in GeneTools
(Syngene by Synoptic Ltd. Cambridge,UK).
Statistical analysis
Data are presented as the mean ± standard deviation.
The non-parametric Mann–Whitney U test was used to
compare means from two independent groups. Pearson
correlation coefficients were computed to investigate cor-
relations between variables. A p-value less than 0.05 indi-
cated statistical significance. SPSS version 20.0 (IBM Inc.,
Chicago, IL) was used for the statistical analyses.
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